CD83+ blood dendritic cells as a vaccine for immunotherapy of metastatic renal-cell cancer
CD83+ blood dendritic cells as a vaccine for immunotherapy of metastatic renal-cell cancer
复制标题
DOI：
10.1016/s0140-6736(05)60748-9
复制
发表时间：
1998-10-24
期刊：
影响因子：
168.9
通讯作者：
Thurnher, M
中科院分区：
文献类型：
--
作者：
Höltl, L;Rieser, C;Thurnher, M
树突状细胞是抗原特异性免疫应答（包括抗肿瘤应答）的最有效刺激物。1-3有效的免疫刺激树突细胞可以从外周血中分离或从循环前体细胞中培养。1-4这些细胞的安全性和有效性目前正在临床试验中进行测试;皮肤，前列腺和B淋巴细胞的数据已经发表。1- 3根据当地伦理委员会批准的方案，我们对转移性肾细胞癌患者的血液树突状细胞进行了初步研究。患者接受至少三次活化的CD 83+树突状细胞4的静脉输注，同时用自体肿瘤细胞裂解物和免疫原性蛋白质钥孔-血蓝蛋白（KLH）填充。每次输注给予5-10106个树突状细胞（微生物无菌试验）。4例患者已入组研究方案，2例患者已完成治疗。
Dendritic cells are the most potent stimulators of antigenspecific immune responses including antitumour responses. 1–3 Potent immunostimulatory dendritic cells can be isolated from peripheral blood or cultured from circulating precursor cells. 1–4 The safety and efficacy of these cells is now being tested in clinical trials; data from skin, prostate, and B-lymphocyte have already been published. 1–3We did a pilot study of cultured blood dendritic cells in patients with metastatic renal-cell carcinoma5 according to a protocol approved by the local ethical committee. Patients receive at least three intravenous infusions of activated, CD83+ dendritic cells4 simultaneously charged with autologous tumour cell lysate and with the immunogenic protein, keyhole-limpet haemocyanin (KLH). 5–10106 dendritic cells (microbiologically tested for sterility) were given per infusion. Four patients have been enrolled in the study protocol and treatment has been completed in two.